Tech Company Financing Transactions

Seismic Therapeutic Funding Round

On 12/4/2023, Seismic Therapeutic secured $121 million in Series B investment from Bessemer Venture Partners, Alexandria Venture Investments and Amgen Ventures.

Transaction Overview

Announced On
12/4/2023
Transaction Type
Venture Equity
Amount
$121,000,000
Round
Series B
Proceeds Purpose
This funds will be used to advance through Phase 1 proof-of-mechanism trials with Seismic's two lead programs: a pan-immunoglobulin (Ig) G protease sculpting (Sc) enzyme candidate (S-1117) and a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody candidate (S-4321). In addition, the Series B will enable the continued growth of the company's pipeline in both the IgSc and DcB product areas, beyond the lead programs. The funding will also enable the company to further expand its proprietary machine learning-enabled IMPACT platform with the development and implementation of additional methods to enhance biologics drug discovery in immunology.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Watertown, MA Undisclosed
USA
Phone
Undisclosed
Email Address
Overview
Seismic Therapeutic is making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. We are an expert team of drug developers integrating machine learning across the entire discovery process to open new, better and faster ways to make medicines for patients.
Profile
Seismic Therapeutic LinkedIn Company Profile
Social Media
Seismic Therapeutic Company Twitter Account
Company News
Seismic Therapeutic News
Facebook
Seismic Therapeutic on Facebook
YouTube
Seismic Therapeutic on YouTube

Management Team

Title
Name
Email & Social
Chairman
Alan Crane
  Alan Crane LinkedIn Profile  Alan Crane Twitter Account  Alan Crane News  Alan Crane on Facebook
Chief Executive Officer
Jo Viney
  Jo Viney LinkedIn Profile  Jo Viney Twitter Account  Jo Viney News  Jo Viney on Facebook
Chief Financial Officer
Edward Freedman
  Edward Freedman LinkedIn Profile  Edward Freedman Twitter Account  Edward Freedman News  Edward Freedman on Facebook
Chief Medical Officer
John Sundy
  John Sundy LinkedIn Profile  John Sundy Twitter Account  John Sundy News  John Sundy on Facebook
Chief Technical Officer
Nathan Higginson-Scott
  Nathan Higginson-Scott LinkedIn Profile  Nathan Higginson-Scott Twitter Account  Nathan Higginson-Scott News  Nathan Higginson-Scott on Facebook
Vice President
Kevin Otipoby
  Kevin Otipoby LinkedIn Profile  Kevin Otipoby Twitter Account  Kevin Otipoby News  Kevin Otipoby on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/4/2023: Rentman venture capital transaction
Next: 12/4/2023: Nth Cycle venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to record tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary